SCHEMBL3354220

SCHEMBL3354220

O=C(O)N1C=CC=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28757079 0.98
SCHEMBL3700149 0.78
SCHEMBL4865079 0.68
SCHEMBL4777651 0.67
SCHEMBL4777648 0.61 CHRM2 (0.30)
SCHEMBL8685790 0.60
SCHEMBL4073685 0.58
SCHEMBL8488893 0.56
SCHEMBL15264190 0.56
Water SCHEMBL8221741 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115023431-B Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 藤济(厦门)生物医药科技有限公司 2024-02-02 CN claimed
CN-115023431-A Triterpenoids, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by group 4 members of the nuclear receptor subfamily 藤济(厦门)生物医药科技有限公司 2022-09-06 CN claimed
WO-2021047672-A1 TRITERPENOID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING NUCLEAR RECEPTOR SUBFAMILY 4 GROUP MEMBER 1-MEDIATED DISEASE IXMEDICINE CO., LTD (CN) 2021-03-18 WO claimed
CN-103249732-A Bacteria topoisomerase II inhibiting 2-thylcarbamoylamino-1, 3-benzothiazol-5-yls BIOTA EUROPE LTD 2013-08-14 CN claimed
CN-101379044-A Heterobicyclic sulfonamide derivatives for the treatment of diabetes HOFFMANN LA ROCHE (CH) 2009-03-04 CN claimed
CN-1984906-A Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC (JP) 2007-06-20 CN claimed
CN-1642917-A Non-peptide GnRH antagonists FERRING BV (NL) 2005-07-20 CN claimed
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 CN disclosed
CN-115023431-B Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 藤济(厦门)生物医药科技有限公司 2024-02-02 CN disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
WO-2023241608-A1 CSF-1R INHIBITORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2023-12-21 WO disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 CN disclosed
EP-4232161-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER Dana-Farber Cancer Institute, Inc. (US) 2023-08-30 EP disclosed
WO-2007062007-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 WO disclosed
WO-2007059229-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-24 WO disclosed
EP-1777225-A1 FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR Japan Tobacco, Inc. (JP) 2007-04-25 EP disclosed
CN-1243735-C 2-iminopyrrolidine derivatives EISAI CO LTD (JP) 2006-03-01 CN disclosed
CN-1649883-A Bicyclic 6-alkylidene-epimycotenes as lactamase inhibitors WYETH CORP (US) 2005-08-03 CN disclosed
CN-1335845-A 3,4-dihydro-2H-benzo[1,4] oxazinyl-methyl [3-(1H-indol-3-yl)-alkyl]-amines AMERICAN HOME PROD (US) 2002-02-13 CN disclosed
CN-1304409-A Indol-3-Yl-cyclohexyl amide derivatives for treatment of depression (5-HT1 receptor antagonists) AMERICAN HOME PROD (US) 2001-07-18 CN disclosed